Alemtuzumab combined with dexamethasone, followed by alemtuzumab maintenance or allo-SCT in “ultra high-risk” CLL: Final results from the CLL2O phase II study

This article has no abstract
Epistemonikos ID: 4de29e7135b474d40917cb81ce8ee9055961edf8
First added on: Feb 06, 2025